대한방사성의약품학회지 (Journal of Radiopharmaceuticals and Molecular Probes)

  • 제9권1호
  • /
  • Pages.3-8
  • /
  • 2023
  • /
  • 2384-1583(pISSN)
  • /
  • 2508-3848(eISSN)
대한방사성의약품학회 (Korean Society of Radiopharmaceuticals and Molecular Probes)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Therapeutic Efficacy using [18F]FP-CIT in 6-OHDA-induced Parkinson's Animal Model

  • Jang Woo Park (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Yi Seul Choi (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Dong Hyun Kim (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Eun Sang Lee (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Chan Woo Park (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Hye Kyung Chung (Korea Radioisotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences) ;
  • Ran Ji Yoo (Department of Nuclear Medicine, Seoul National University Hospital, College of Medicine)
  • 투고 : 2023.06.08
  • 심사 : 2023.06.14
  • 발행 : 2023.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Parkinson's disease is a neurodegenerative disease caused by damage to brain neurons related to dopamine. Non-clinical animal models mainly used in Parkinson's disease research include drug-induced models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine, and genetically modified transgenic animal models. Parkinson's diagnosis can be made using brain imaging of the substantia nigra-striatal dopamine system and using a radiotracer that specifically binds to the dopamine transporter. In this study, 18F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane was used to confirm the image evaluation cutoff between normal and parkinson's disease models, and to confirm model persistence over time. In addition, the efficacy of single or combined administration of clinically used therapeutic drugs in parkinson's animal models was evaluated. Image analysis was performed using the PMOD software. Converted to standardized uptake value, and analyzed by standardized uptake value ratio by dividing the average value of left striatum by the average value of right striatum obtained by applying positron emission tomography images to the atlas magnetic resonance template. The image cutoff of the normal and the parkinson's disease model was calculated as SUVR=0.829, and it was confirmed that it was maintained during the test period. In the three-drug combination administration group, the right and left striatum showed a high symmetry of more than 0.942 on average and recovered significantly. Images using 18F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl) nortropane are thought to be able to diagnose and evaluate treatment efficacy of non-clinical Parkinson's disease.

키워드

과제정보

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단(No. 2021R1C1C2004706)과 과학기술정보통신부 한국원자력의학원 연구운영비지원사업(No. 50539-2023)의 지원을 받아 수행하였으며 다른 상업적 이해관계는 없음.

참고문헌

  1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primer 2017;3:17013.
  2. Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol 2014;10(12):708-22. https://doi.org/10.1038/nrneurol.2014.205
  3. NIH National Institute on Aging. Parkinson's Disease: Causes, Symptoms, and Treatments. National Institute on Aging. Available from: https://www.nia.nih.gov/health/parkinsons-disease
  4. Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies. Bosn J Basic Med Sci 2021;21(4):422-33.
  5. Meredith GE, Rademacher DJ. MPTP Mouse Models of Parkinson's Disease: An Update. J Park Dis 2011;1(1):19-33.
  6. Requejo C, Lopez-de-Ipina K, Ruiz-Ortega JA, Fernandez E, Calvo PM, Morera-Herreras T, Miguelez C, Cardona-Grifoll L, Cepeda H, Ugedo L, Lafuente JV. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson's Disease: Exploring Prodromal Biomarkers. Front Neurosci 2020;14.
  7. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 2007;11(3-4):151-67. https://doi.org/10.1007/BF03033565
  8. Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model. Neurol Engl Ed 2017;32(8):533-9. https://doi.org/10.1016/j.nrleng.2015.06.019
  9. Lewy body. Wikipedia 2023. Available from: https://en.wikipedia.org/w/index.php?title=Lewy-body&oldid=1143469951
  10. Kaczynska K, Andrzejewski K. Chapter 40-6-hydroxydopamine-induced model of Parkinson's disease. Genetics, Neurology, Behavior, and Diet in Parkinson's Disease 2020. p. 627-42.
  11. Harvey BK, Wang Y, Hoffer BJ. Transgenic rodent models of Parkinson's disease. Acta Neurochir Suppl 2008;101:89-92. https://doi.org/10.1007/978-3-211-78205-7_15
  12. Fernagut PO, Chesselet MF. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 2004;17(2):123-30. https://doi.org/10.1016/j.nbd.2004.07.001
  13. Benamer HTS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MHIM, Sips HJWA, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2000;15(3):503-10. https://doi.org/10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V
  14. Park E. A New Era of Clinical Dopamine Transporter Imaging Using 123I-FP-CIT. Journal of Nuclear Medicine Technology 2012;40(4):222-8 https://doi.org/10.2967/jnmt.112.111617
  15. Han S, Oh M, Oh JS, Lee SJ, Oh SJ, Chung SJ, Park HK, Kim JS. Subregional pattern of striatal dopamine transporter loss on 18F FP-CIT positron emission tomography in patients with pure akinesia with gait freezing. JAMA Neurol 2016;73(12):1477-84. https://doi.org/10.1001/jamaneurol.2016.3243
  16. Santoro M, Fadda P, Klephan KJ, Hull C, Teismann P, Platt B, Riedel G. Neurochemical, histological, and behavioral profiling of the acute, sub-acute, and chronic MPTP mouse model of Parkinson's disease. J Neurochem 2023;164(2):121-42. https://doi.org/10.1111/jnc.15699
  17. Brooks SP, Dunnett SB. Tests to assess motor phenotype in mice: a user's guide. Nat Rev Neurosci 2009;10(7):519-29. https://doi.org/10.1038/nrn2652
  18. Gomez-Benito M, Granado N, Garcia-Sanz P, Michel A, Dumoulin M, Moratalla R. Modeling Parkinson's Disease With the Alpha-Synuclein Protein. Front Pharmacol 2020;11.
  19. Oh M, Lee N, Kim C, Son HJ, Sung C, Oh SJ, Lee SJ, Chung SJ, Lee CS, Kim JS. Diagnostic accuracy of dual-phase 18F-FP-CIT PET imaging for detection and differential diagnosis of Parkinsonism. Sci Rep 2021;11(1):14992.
  20. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5(1):107-10. https://doi.org/10.1016/0014-2999(68)90164-7
  21. Schwarting RK, Huston JP. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996;50(2-3):275-331. https://doi.org/10.1016/S0301-0082(96)00040-8
  22. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007;2(1):141-51. https://doi.org/10.1038/nprot.2006.342
  23. Dauer W, Przedborski S. Parkinson's Disease: Mechanisms and Models. Neuron 2003;39(6):889-909. https://doi.org/10.1016/S0896-6273(03)00568-3
  24. Jackson-Lewis V, Blesa J, Przedborski S. Animal models of Parkinson's disease. Parkinsonism Relat Disord 2012;18:S183-5. https://doi.org/10.1016/S1353-8020(11)70057-8
  25. Liu XL, Liu SY, Barret O, Tamagnan GD, Qiao HW, Song TB, Lu J, Chan P. Diagnostic value of striatal 18F-FP-DTBZ PET in Parkinson's disease. Front Aging Neurosci 2022;14.
  26. Meyer PF, McSweeney M, Gonneaud J, Villeneuve S. AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science 2019. p. 63-106.
  27. Kordys E, Apetz N, Schneider K, Duncan E, Buschbell B, Rohleder C, Sue M, Drzezga A, Neumaier B, Timmermann L, Endepols H. Motor impairment and compensation in a hemiparkinsonian rat model: correlation between dopamine depletion severity, cerebral metabolism and gait patterns. EJNMMI Res 2017;7(1):68.
  28. Abrams JH, Schulman P, White WB. Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with intravenous labetalol. N Engl J Med 1985;313(1):52.
  29. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012;211:51-76. https://doi.org/10.1016/j.neuroscience.2011.10.057
  30. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318(1):215-24. https://doi.org/10.1007/s00441-004-0938-y